Key clinical point : Platinum-doublet chemotherapy as the second-line treatment may offer an overall survival (OS) advantage over cytotoxic chemotherapy without platinum in relapsed patients with unresectable stage III non–small-cell lung cancer (NSCLC).
Major finding : The platinum group had a longer survival than the nonplatinum group (median OS 21.5 vs. 10.5 months; hazard ratio [HR] 0.54; P < .001). The platinum group also had longer survival than the nonplatinum group, when assessed from the beginning of chemoradiotherapy (median OS 34.9 vs. 21.8 months; HR 0.58; P = .001).
Study details : The data come from a retrospective cohort study that included 320 patients with unresectable stage III NSCLC from a Japanese lung cancer registry.
Disclosures: The study was funded by the Japan Society for Respiratory Endoscopy, Japanese Association for Thoracic Surgery, Japanese Association for Chest Surgery, Japanese Respiratory Society, and Japan Lung Cancer Society. E Miyawaki, K Takahashi, E Miyaoka, I Yoshino, and H Date did not report any disclosures. The other authors reported ties with one or more pharmaceutical companies.
Source: Miyawaki E et al. Efficacy of platinum agents for stage III non–small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer. 2022;22:342 (Mar 29). Doi: 10.1186/s12885-022-09441-3